2024
U.S. policy responses to xylazine: Thinking bigger
Harvey L, Green T, Park J, Rich J. U.S. policy responses to xylazine: Thinking bigger. International Journal Of Drug Policy 2024, 130: 104517. PMID: 39003892, DOI: 10.1016/j.drugpo.2024.104517.Peer-Reviewed Original ResearchXylazine awareness, desire, use and exposure: Preliminary findings from the Rhode Island community-based drug checking cohort study
Park J, Serafinski R, Ujeneza M, McKenzie M, Tardif J, Krotulski A, Badea A, Grossman E, Green T. Xylazine awareness, desire, use and exposure: Preliminary findings from the Rhode Island community-based drug checking cohort study. Drug And Alcohol Dependence Reports 2024, 11: 100247. PMID: 38974777, PMCID: PMC11225690, DOI: 10.1016/j.dadr.2024.100247.Peer-Reviewed Original ResearchDrug checking servicesCohort studyAt-risk individualsHarm reduction organizationsIncrease community knowledgeHarm reductionRapid careXylazine exposureReduction educationDecrease harmPWUDCommunity knowledgeParticipantsCareChecking servicesReceptor agonistsAnalyzed dataHarmRhode IslandLiquid chromatography quadrupole-time-of-flight mass spectrometryQuadrupole-time-of-flight mass spectrometryMass spectrometryPreliminary findingsPolicies, adaptations, and ongoing challenges to naloxone, buprenorphine and nonprescription syringe access across four-states: Findings from an environmental scan and key informant interviews
Floyd A, Silcox J, Strickler G, Nong T, Blough M, Bolivar D, Rabin M, Bratberg J, Irwin A, Hartung D, Hansen R, Bohler R, Green T. Policies, adaptations, and ongoing challenges to naloxone, buprenorphine and nonprescription syringe access across four-states: Findings from an environmental scan and key informant interviews. Drug And Alcohol Dependence Reports 2024, 11: 100243. PMID: 38948428, PMCID: PMC11214408, DOI: 10.1016/j.dadr.2024.100243.Peer-Reviewed Original ResearchNonprescription syringesImplementation of evidence-based interventionsEnvironmental scanEvidence-based interventionsCost of medicationsSemi-structured interviewsHarm reduction organizationsPatients' stigmaNaloxone standing orderRural settingsStanding ordersActive partnershipPharmacy policiesPharmacy chainInformant interviewsStructural barriersMedicaid coverageSyringe accessDispensing buprenorphineInstitutionalized interventionsPharmacyMortality increaseKey informantsRandomized trialsInterventionPilot findings on the real-world performance of xylazine test strips for drug residue testing and the importance of secondary testing methods
Thompson E, Tardif J, Ujeneza M, Badea A, Green T, McKee H, McKenzie M, Park J. Pilot findings on the real-world performance of xylazine test strips for drug residue testing and the importance of secondary testing methods. Drug And Alcohol Dependence Reports 2024, 11: 100241. PMID: 38808200, PMCID: PMC11131062, DOI: 10.1016/j.dadr.2024.100241.Peer-Reviewed Original ResearchEvaluation of Strategies to Enhance Community-Based Naloxone Distribution Supported by an Opioid Settlement
Zang X, Skinner A, Krieger M, Behrends C, Park J, Green T, Walley A, Morgan J, Linas B, Yedinak J, Schackman B, Marshall B. Evaluation of Strategies to Enhance Community-Based Naloxone Distribution Supported by an Opioid Settlement. JAMA Network Open 2024, 7: e2413861. PMID: 38814644, PMCID: PMC11140538, DOI: 10.1001/jamanetworkopen.2024.13861.Peer-Reviewed Original ResearchConceptsCommunity-based naloxone distributionOpioid overdose deathsNaloxone distributionSolitary drug useOpioid overdoseNaloxone distribution programsDecision analytical model studyDrug useNonfatal opioid overdoseReducing opioid overdose deathsIncreasing naloxone distributionHypothetical interventionMain OutcomesNaloxone availabilityCommunity-based naloxone distribution programsStudy populationOverdose deathsInterventionAnnual numberUS statesMisuse opioidsAnalytical model studyRhode IslandPublished simulation modelSynergistic associationLatinX harm reduction capital, medication for opioid use disorder, and nonfatal overdose: A structural equation model analysis among people who use drugs in Massachusetts
Shrestha S, Stopka T, Hughto J, Case P, Palacios W, Reilly B, Green T. LatinX harm reduction capital, medication for opioid use disorder, and nonfatal overdose: A structural equation model analysis among people who use drugs in Massachusetts. Drug And Alcohol Dependence 2024, 259: 111293. PMID: 38643530, DOI: 10.1016/j.drugalcdep.2024.111293.Peer-Reviewed Original ResearchStructural equation modeling analysisSubstance use historyOpioid use disorderUse disorderStructural equation modelingTreatment utilizationGeneralized structural equation modelMethadone treatmentLatent constructsBuprenorphine treatmentSelf-identificationNonfatal overdoseMeasured constructsEquation modelingLatinxMOUD useTreatment experienceOpioidMOUDTreatment differencesModel analysisOverdoseHarm reduction servicesOpioid overdoseDifferential utilizationThe association between naloxone claims and proportion of independent versus chain pharmacies: A longitudinal analysis of naloxone claims in the United States
Freibott C, Jalali A, Murphy S, Walley A, Linas B, Jeng P, Bratberg J, Marshall B, Zang X, Green T, Morgan J. The association between naloxone claims and proportion of independent versus chain pharmacies: A longitudinal analysis of naloxone claims in the United States. Journal Of The American Pharmacists Association 2024, 64: 102093. PMID: 38604474, DOI: 10.1016/j.japh.2024.102093.Peer-Reviewed Original ResearchNaloxone dispensing ratesChain pharmaciesDispensing ratesNaloxone dispensingIndependent pharmaciesUrban-rural classificationNaloxone access lawsLongitudinal analysisAccess lawsOpioid mortality ratesRates of naloxoneUrban/rural designationCounty typesNaloxone availabilityPrimary exposurePrimary outcomeNational studyCounty-levelPharmacyQuarter-yearTwo-sample t-testPopulation characteristicsCo-prescribedSymphony HealthT-test“Wanna cry this out real quick?”: an examination of secondary traumatic stress risk and resilience among post-overdose outreach staff in Massachusetts
Schoenberger S, Cummins E, Carroll J, Yan S, Lambert A, Bagley S, Xuan Z, Green T, Cook F, Yule A, Walley A, Formica S. “Wanna cry this out real quick?”: an examination of secondary traumatic stress risk and resilience among post-overdose outreach staff in Massachusetts. Harm Reduction Journal 2024, 21: 66. PMID: 38504244, PMCID: PMC10949647, DOI: 10.1186/s12954-024-00975-2.Peer-Reviewed Original ResearchConceptsCompassion fatigueProgram staffOutreach staffOutreach programsSelf-care practicesTraumatic stressAnalysis of semi-structured interviewsOutreach workCompassion fatigue resiliencyProtective factorsSemi-structured interviewsExperience of stressOutreach teamsPotential protective factorsSocial supportWorkplace supportOverdose survivorsCoping strategiesOverdose eventsStaff membersCompassionate serviceStaffFatigue resilienceWell-beingJob satisfaction“I go out of my way to give them an extra smile now:” A study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materials
Irwin A, Gray M, Ventricelli D, Boggis J, Bratberg J, Floyd A, Silcox J, Hartung D, Green T. “I go out of my way to give them an extra smile now:” A study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materials. Research In Social And Administrative Pharmacy 2024, 20: 512-519. PMID: 38395644, PMCID: PMC10981567, DOI: 10.1016/j.sapharm.2024.02.001.Peer-Reviewed Original ResearchHarm reduction materialsOpioid use disorderFocus groupsCommunity pharmacy interventionsImmersion-crystallization approachUse disorderNonprescription syringe salesStudy of pharmacistsHealth of peopleAcademic detailingMulticomponent interventionReduce stigmaPharmacy interventionsNon-HispanicNonprescription syringesPharmacists' perspectivesCommunity pharmacistsImplementation barriersCommunity pharmaciesPharmacists' attitudesNaloxone provisionQualitative data analysisPharmacistsSyringe salesHealth suppliesPrivacy and confidentiality in Massachusetts' post-overdose outreach programs: Mixed methods analysis of outreach staff surveys and interviews
Beaugard C, Formica S, Cummins E, Bagley S, Beletsky L, Green T, Murray S, Yan S, Xuan Z, Walley A, Carroll J. Privacy and confidentiality in Massachusetts' post-overdose outreach programs: Mixed methods analysis of outreach staff surveys and interviews. International Journal Of Drug Policy 2024, 124: 104310. PMID: 38181671, DOI: 10.1016/j.drugpo.2023.104310.Peer-Reviewed Original ResearchRelationships Between Stigma, Risk Tolerance, and Buprenorphine Dispensing Intentions Among Community-Based Pharmacists: Results From a National Sample
Light A, Green T, Freeman P, Zadeh P, Burns A, Hill L. Relationships Between Stigma, Risk Tolerance, and Buprenorphine Dispensing Intentions Among Community-Based Pharmacists: Results From a National Sample. Substance Use & Addiction Journal 2024, 45: 211-221. PMID: 38258805, DOI: 10.1177/29767342231215178.Peer-Reviewed Original ResearchThe Cost of Safe Injection: Insights on Nonprescription Syringe Price Variability From Systematic Secret Shopping
Blough M, Rocha A, Bratberg J, Silcox J, Bolivar D, Floyd A, Gray M, Green T. The Cost of Safe Injection: Insights on Nonprescription Syringe Price Variability From Systematic Secret Shopping. Substance Use & Addiction Journal 2024, 45: 201-210. PMID: 38258818, DOI: 10.1177/29767342231217831.Peer-Reviewed Original Research
2023
Costing analysis of a point-of-care drug checking program in Rhode Island
Cepeda J, Thompson E, Ujeneza M, Tardif J, Walsh T, Morales A, Rosen J, Green T, Park J. Costing analysis of a point-of-care drug checking program in Rhode Island. Drug And Alcohol Dependence 2023, 253: 111028. PMID: 38000322, PMCID: PMC11238094, DOI: 10.1016/j.drugalcdep.2023.111028.Peer-Reviewed Original ResearchResearch Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy
Jarrett J, Bratberg J, Burns A, Cochran G, DiPaula B, Dopp A, Elmes A, Green T, Hill L, Homsted F, Hsia S, Matthews M, Ghitza U, Wu L, Bart G. Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy. Substance Abuse 2023, 44: 264-276. PMID: 37902032, PMCID: PMC10870734, DOI: 10.1177/08897077231203849.Peer-Reviewed Original ResearchConceptsOpioid use disorderNational Drug Abuse Treatment Clinical Trials NetworkOUD treatmentCommunity pharmaciesDrug Abuse's National Drug Abuse Treatment Clinical Trials NetworkUse disordersOpioid use disorder treatmentFifth of peoplePrimary care settingBenefits of medicationsClinical Trials NetworkUse disorder treatmentHealth service modelClinical service provisionOpioid overdose crisisPatient populationCommunity pharmacy sectorPatient outcomesCare settingsMOUD servicesDisorder treatmentSynthetic opioidsChain pharmaciesTrials NetworkMOUD